Genome editing improves blood clotting in mice with hemophilia B

June 28, 2011, Howard Hughes Medical Institute

(Medical Xpress) -- Scientists have used a gene therapy tool that acts like intelligent molecular scissors to correct the key gene defect in mice with hemophilia B, a disease that can lead to uncontrolled bleeding. The intervention improved the animals’ blood clotting enough that their severe disease was reduced to a mild form.

Hemophilia B affects about 3,000 men and boys in the United States. People with hemophilia can experience uncontrolled bleeding, including spontaneous and life-threatening bleeding into the joints or the central nervous system. In severe cases, patients must undergo a lifetime of clotting factor infusions to control bleeding.

“People had already shown you could do this kind of genome editing, but only in cells you could take out, manipulate in the laboratory and put back in the patient," said
Katherine A. High.

The disease is caused by defects in the blood clotting factor called Factor IX. Repairing that could eliminate the disease. One possible gene therapy strategy is to use molecular tools called zinc-finger nucleases, which allow scientists to snip out and correct specific DNA defects. So far, this approach has only been used successfully to edit genes in isolated cells, but now, in what may be a significant advance in gene therapy research, Howard Hughes Medical Institute investigator Katherine A. High has broken that barrier. Her team’s work is published in the June 26, 2011, issue of the journal Nature.

Zinc fingers are a natural part of the genetic machinery in organisms from yeast to humans, and each one’s finger-like structure binds to a specific sequence of DNA. By linking these DNA-binding molecules to DNA-snipping enzymes called nucleases, scientists have created molecular scissors that can be targeted to specific parts of the genome.

The zinc-finger approach is more precise than conventional gene therapy, in which whole genes are introduced to cells to counteract the action of mutated genes. When those genes insert into the cell’s genome, it’s anybody’s guess where they’ll land. “There is some possibility of integration of the donated DNA in untoward sites that may, for example, promote tumor formation,” says High explaining one risk of conventional gene therapy. “If you could do genome editing, you could get a site-specific correction.”

In laboratory cell cultures, zinc-finger nucleases can be targeted to home to a specific site on the genome and snip double-stranded DNA in two. Sensing the disruption, the cell rushes to repair the break, often by copying nearby homologous DNA. Scientists take advantage of that tendency by administering a strand of flawless DNA designed to correct the mutated gene along with the . If all goes well, the cell’s own DNA repair proteins copy the flawless strand into the cellular DNA, and, voilà, a perfect gene where a broken one once lived.

“People had already shown you could do this kind of genome editing, but only in cells you could take out, manipulate in the laboratory and put back in the patient,” said High, whose lab is at the Children’s Hospital of Philadelphia. In the new work, High’s team repaired the defective gene responsible for hemophilia in living mice, and the correction was maintained in new cells when the treated cells divided.

Key to making this work, High said, was using adeno-associated virus to carry both the DNA strand and the zinc-finger nuclease into the mouse liver. This virus, engineered from naturally occurring parvovirus, heads straight to the liver when injected intravenously. The liver is the main source of the factors missing in hemophilia.

To be used for gene therapy, zinc-finger nucleases must be designed to specifically target the defective segment of DNA. Working with collaborators at Sangamo BioSciences, High tested a number of zinc-finger nucleases that the California company had engineered to target various portions of the gene that encodes Factor IX, the clotting factor that fails to work in patients with in .

Serendipitously, the zinc-finger nuclease that most efficiently snipped out the Factor IX DNA was the one that allowed her to simultaneously target all of the gene’s commonly mutated segments. “We didn’t know whether among all of the [zinc-finger nucleases] that were designed, this one would succeed,” she said. “This turned out to be the most efficient, which was fortuitous.”

When the mice with severe hemophilia B were treated with the Factor IX zinc-finger nucleases, the clotting factors in their blood increased to a level that is considered mild disease. Most individuals with hemophilia B have less than 1 percent of normal clotting factors. An increase of clotting factor to 5 percent of normal transforms severe hemophilia into mild . “That doesn’t mean you can play football, but it does mean you can play tennis,” High said. “In these mice we got levels ranging from 3 percent to 7 percent.”

“I think that there were a couple of keys to our success,” she said. “We used a highly efficient method of delivery to the liver, and, secondly, the zinc-finger nucleases we used were very efficient.”

High says further work will be needed to translate her team’s work in the laboratory into safe, effective treatments for patients, but the new findings are promising for the future of .

Explore further: Genome editing, a next step in genetic therapy, corrects hemophilia in animals

Related Stories

Genome editing, a next step in genetic therapy, corrects hemophilia in animals

June 26, 2011
Using an innovative gene therapy technique called genome editing that hones in on the precise location of mutated DNA, scientists have treated the blood clotting disorder hemophilia in mice. This is the first time that genome ...

Collaborative develops drug that may help hemophilia patients

June 27, 2011
A razor nick in the shower? A fall on a slippery floor? The average person simply calls it bad karma, but for people with hemophilia such episodes can cause prolonged blood loss.

Recommended for you

Discovery of the 'pioneer' that opens the genome

January 23, 2018
Our genome contains all the information necessary to form a complete human being. This information, encoded in the genome's DNA, stretches over one to two metres long but still manages to squeeze into a cell about 100 times ...

Researchers identify gene responsible for mesenchymal stem cells' stem-ness'

January 22, 2018
Many doctors, researchers and patients are eager to take advantage of the promise of stem cell therapies to heal damaged tissues and replace dysfunctional cells. Hundreds of ongoing clinical trials are currently delivering ...

Genes contribute to biological motion perception and its covariation with autistic traits

January 22, 2018
Humans can readily perceive and recognize the movements of a living creature, based solely on a few point-lights tracking the motion of the major joints. Such exquisite sensitivity to biological motion (BM) signals is essential ...

Peers' genes may help friends stay in school, new study finds

January 18, 2018
While there's scientific evidence to suggest that your genes have something to do with how far you'll go in school, new research by a team from Stanford and elsewhere says the DNA of your classmates also plays a role.

Two new breast cancer genes emerge from Lynch syndrome gene study

January 18, 2018
Researchers at Columbia University Irving Medical Center and NewYork-Presbyterian have identified two new breast cancer genes. Having one of the genes—MSH6 and PMS2—approximately doubles a woman's risk of developing breast ...

A centuries-old math equation used to solve a modern-day genetics challenge

January 18, 2018
Researchers developed a new mathematical tool to validate and improve methods used by medical professionals to interpret results from clinical genetic tests. The work was published this month in Genetics in Medicine.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.